Research progress on icariin, a traditional Chinese medicine extract, in the treatment of asthma
Allergol. immunopatol
; 50(1): 9-16, ene 2, 2022.
Artigo
em Inglês
| IBECS
| ID: ibc-203093
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
Bronchial asthma is a common chronic airway disease, and long-term management of asthma is the focus and challenge of clinical treatment. Glucocorticoids are often used as the first choice for the treatment of asthma. However, the occurrence of hormone dependence, hormone resistance, and local and systemic adverse reactions caused by hormone application also creates problems for the treatment of asthma. Finding new, safe, and effective therapeutic drugs is an important research direction at present. Icariin is an effective ingredient of the traditional Chinese medicine, Epimedium. It has various biological attributes such as anti-inflammatory and antioxidative activities, and immune regulation. It has high safety and a wide range of clinical applications. Icariin has the characteristics of multitargeted intervention in the treatment of asthma. Here, we review the specific mechanisms of icariin in treating asthma, and icariin is considered a novel therapy in controlling asthma; however, the mechanism is still worth further investigation (AU)
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Asma
/
Medicamentos de Ervas Chinesas
/
Extratos Vegetais
/
Epimedium
/
Medicina Tradicional Chinesa
Limite:
Humanos
Idioma:
Inglês
Revista:
Allergol. immunopatol
Ano de publicação:
2022
Tipo de documento:
Artigo
Instituição/País de afiliação:
Hospital of Naval Medical University/China